 My name is Ulka Vaishimpayan and I am the chair of the GU multidisciplinary team at Barbara and Carmina's Cancer Institute in Detroit, Michigan. This cancer center is an NCI designated Comprehensive Cancer Center and affiliated with Wayne State University in Michigan as well. My practice and focus is genitourinary cancer specifically within kidney cancer. My clinical practice is focused on kidney cancer along with as well as my clinical research is focused on kidney cancer as well. Patients get the awareness of not just new treatments because new treatments are frequently publicized all over the press, TV, newspapers, whatever. But they also realize or can the information is transmitted about how we are fine-tuning the existing therapies to serve them better. And the optimal treatment is still being decided for an individual patient and we are really at the beginning of getting different genetic markers that may help us predict response. My presentation today is focusing within patient management issues of the disparities in treatment of kidney cancer. So even though we've improved outcomes tremendously the last few years in kidney cancer, that in itself has caused a huge disparity gap to widen between the different people who don't have access to treatment, who have multiple other comorbid conditions that interfere with them receiving the optimal treatment. And of course, you know, race and socioeconomic factors as well as the biological factors within the cancer that induce all of these disparities. I think what patients should ask first of all is what is going to be the overall treatment plan. So not just the type of medication but how are different modalities going to be integrated into their treatment. So probably the question needs to be is am I a candidate for both surgery as well as receiving treatment by in terms of different targeted therapies or is it just going to be targeted therapies or some kind of systemic therapy first followed by the consideration of local therapies. So I think patients should be more aware in asking questions about consideration of multidisciplinary care. The other thing I think patients should become more aware of and be asking about is are there any clinical trials that are appropriate to my situation. Because typically what we find is that clinical trials in kidney cancers especially in the last few years have represented the most cutting edge type of treatment and has benefited majority of the patients who have enrolled on it. So I would say those would probably be the top two questions I would recommend patients ask.